Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma (Q39308923)

10 September 2017

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma (English)

1 reference

10 September 2017

H Tamura

1

1 reference

10 September 2017

M Ishibashi

2

1 reference

10 September 2017

T Yamashita

3

1 reference

10 September 2017

S Tanosaki

4

1 reference

10 September 2017

N Okuyama

5

1 reference

10 September 2017

A Kondo

6

1 reference

10 September 2017

H Hyodo

7

1 reference

10 September 2017

E Shinya

8

1 reference

10 September 2017

H Takahashi

9

1 reference

10 September 2017

H Dong

10

1 reference

10 September 2017

K Tamada

11

1 reference

10 September 2017

L Chen

12

1 reference

10 September 2017

K Dan

13

1 reference

10 September 2017

K Ogata

14

1 reference

10 September 2017

25 July 2012

1 reference

10 September 2017

1 reference

10 September 2017

27

1 reference

10 September 2017

464-472

1 reference

10 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.213

10 September 2017

0 references

cites work

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Immunology of B7-H1 and its roles in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Interaction of human PD-L1 and B7-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Multiple myeloma: biology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Role of Bcl-2 family of proteins in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

CD28-mediated regulation of multiple myeloma cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

7 January 2021

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

7 January 2021

Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

7 January 2021

Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.213

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.213

1 reference

10 September 2017

1 reference